Comparison of class Ia/Ib versus class III antiarrhythmic drugs for the suppression of inducible sustained ventricular tachycardia associated with coronary artery disease

American Journal of Cardiology

Volumn 80, Issue 5, 1997, Pages 591-594

  Khalighi, Koroush ^a   Peters, Robert W ^a   Feliciano, Zenaida ^a   Shorofsky, Stephen R ^a   Gold, Michael R ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; ANTIARRHYTHMIC AGENT; DISOPYRAMIDE; MEXILETINE; PHENYTOIN; PROCAINAMIDE; QUINIDINE; SOTALOL; TOCAINIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; FEMALE; HEART VENTRICLE PACING; HEART VENTRICLE TACHYCARDIA; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030886667     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00427-X     Document Type: Article

References (22)

1. Anderson JL. Implantable defibrillators are preferable to pharmacologic therapy for patients with ventricular tachyarrhythmias: an antagonists viewpoint. Progr Cardiovasc Dis 1996;38:393-400.
2. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993;329:452-458.
3. Foster MT, Peters RW, Froman D, Shorofsky SR, Gold MR. Electrophysiologic effects and predictors of success of combination therapy with class Ia and Ib antiarrhythmic drugs for sustained ventricular arrhythmias. Am J Cardiol 1996;78:47-50.
4. Pratt CM, Eaton T, Francis M, Woolbert S, Mahmarian J, Roberts R, Young JB. The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio. Am Heart J 1989;118:433-440.
5. Stanton MS, Prystowsky EN, Fineberg NS, Miles WM, Zipes DP, Heger JJ. Arrhythmogenic effects of antiarrhythmic drugs: a study of 506 patients treated for ventricular tachycardia or fibrillation. J Am Coll Cardiol 1989;14:209-215.
6. Slater W, Lampert S, Podrid PJ, Lown B. Clinical predictors of arrhythmia worsening by antiarrhythmic drugs. Am J Cardiol 1988;61:349-353.
7. Duff HJ, Roden D, Primm RK, Oates JA, Woosley RL. Mexiletine in the treatment of resistant ventricular arrhythmias: enhancement of efficacy and reduction of dose-related side effects by combination with quinidine. Circulation 1983;67:1124-1128.
8. Greenspan AM, Spielman SR, Webb CR, Sokoloff NM, Rae AP, Horowitz LN. Efficacy of combination therapy with mexiletine and a type Ia agent for inducible ventricular tachyarrhythmias secondary to coronary artery disease. Am J Cardiol 1985;56:277-284.
9. Whitford EG, McGovern B, Schoenfeld MH, Garan H, Newell JB, McElroy M, Ruskin JN. Long-term efficacy of mexiletine alone and in combination with class Ia antiarrhythmic drugs for refractory ventricular arrhythmias. Am Heart J 1988;115:360-366.
10. Swerdlow CD, Gong G, Echt DS, Winkle RA, Griffin JC, Ross DL, Mason JW. Clinical factors predicting successful electrophysiologic-pharmacologic study in patients with ventricular tachycardia. J Am Coll Cardiol 1983;1:409-416.
11. Wilber DJ, Garan H, Finkelstein D, Kelly E, Newell J, McGovern B, Ruskin JN. Out of hospital cardiac arrest: use of electrophysiologic testing in the prediction of long-term outcome. N Engl J Med 1988;318:19-24.
12. Kuchar DL, Rottman J, Berger E, Freeman CS, Garan H, Ruskin JN. Prediction of successful suppression of sustained ventricular tachyarrhythmias by serial drug testing from data derived at the initial electrophysiologic study. J Am Coll Cardiol 1988;12:982-988.
13. Moss AJ, Hall J, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Sakseena S, Waldo AL, Wilber D, Brown MW, Heo M. Improved survival with an implanted defibrilator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933-1940.
14. Hirsowitz G, Podrid PJ, Lampert S, Stein J, Lown B. The role of beta blocking agents as adjunct therapy to membrane stabilizing drugs in malignant ventricular arrhythmia. Am Heart J 1986;111:852-860.
15. Ross DL, Sze DY, Keefe DL, Swerdlow CD, Echt DS, Griffin JC, Winkle RA, Mason JW. Antiarrhythmic drug combinations in the treatment of ventricular tachycardia: efficacy and electrophysiologic effects. Circulation 1982;66:1205-1210.
16. Brodsky MA, Chough SP, Allen BJ, Caparelli EV, Orlov MV, Caudillo G. Adjuvant meteprolol improves efficacy of class I antiarrhythmic drugs in patients with inducible sustained monomorphic ventricular tachycardia. Am Heart J 1988;124:629-635.
17. Beta Blocker Heart Attack Study Group. The Beta Blocker Heart Attack Trial. JAMA 1981;246:2073-2080.
18. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-809.
19. Das S, Morady F, DiCarlo L, Baerman J, Krol R, De Buitleir M, Crevey B. Prognostic usefulness of programmed stimulation in idiopathic dilated cardiomyopathy without symptomatic ventricular arrhythmias. Am J Cardiol 1986;58: 998-1000.
20. Poll D, Marchlinski F, Buxton A, Josephson M. Usefulness of programmed stimulation in idiopathic dilated cardiomyopathy. Am J Cardiol 1986;58:992-997.
21. Josephson ME, Horowitz LN. Electrophysiologic approach to the therapy of recurrent sustained ventricular tachycardia. Am J Cardiol 1979;43:631-642.
22. Mason JW, Winkle RA. Accuracy of the ventricular tachycardia induction study for predicting long-term efficacy and inefficacy of antiarrhythmic drugs. N Engl J Med 1980;303:1073-1079.